chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Febrile seizure, high fevers up to 102.8  starting evening of 12/17, 8 days after first MMR vaccination (no varicella) with a 10s febrile seizure noted - eyes open, absence/staring with rhythmic full body myoclonus, unresponsive, cried after event.  Abrupt, intense whole body Myoclonus continued throughout 12/18, high fevers, involuntary facial twitches while Awake, unsteady gait, walking into walls/furniture as if in a daze,   All symptoms present without presence of any other illness or infection; no uri symptoms (sneeze cough or runny nose, current or recent, no pain signs related to ears, mouth, or throat. No gi symptoms (eating and drinking, no vomiting no diarrhea) no gu symptoms (abnormal urine) integumentary (no rashes)   6.5 year old male sibling had same symptoms after MMRV vaccination, later diagnosed with epilepsy and subsequent childhood apraxia of speech.
G62.9 NEUROPATHY 11/23/2021 ATYPICAL CHEST PAIN I21.4 ACUTE NON ST ELEVATION MI 4/2/2023 ATYPICAL CHEST PAIN G62.9 NEUROPATHY 11/23/2021 ACUTE NON ST ELEVATION MI    CHEST PAIN I21.4 ACUTE NON ST ELEVATION MI 4/2/2023 ACUTE NON ST ELEVATION MI    CHEST PAIN G62.9 NEUROPATHY 11/23/2021 CAD (CORONARY ARTERY DISEASE) WO ANGINA I21.4 ACUTE NON ST ELEVATION MI 4/2/2023 CAD (CORONARY ARTERY DISEASE) WO ANGINA
fever blisters; This spontaneous report was received from a pharmacist refers to a 56 years old female patient. The patient's medical history, concurrent conditions and concomitant medications were unknown. On 07-FEB-2019 (Thursday), the patient was vaccinated pneumococcal Vaccine, Polyvalent (23-valent) (PNEUMOVAX23) (dose, frequency, route of administration not given) (lot# R018735 and expiry date: 06-APR-2020) for an prophylaxis. On the same day, the patient was also vaccinated with some flu vaccine (details unspecified). On 08-FEB-2019 (Friday), the patient experienced reaction which was fever blister on her mouth which she had never before. The outcome of the event fever blister was unknown. The reporter considered fever blister to be not related with pneumococcal Vaccine, Polyvalent (23-valent) (PNEUMOVAX23) and the flu vaccine. The reporter further added that the patient had never received (PREVNAR 13) and it was that topical cream which caused the fever blisters.
Myalgia, Fever, FATIGUE, ARM PAIN Narrative: MISSED WORK DUE TO SYMPTOMS
Menstrual bleeding and heavy cramping beginning two days after the 2nd COVID vaccine dose.  Patient is not due to start next period for another 2-3 weeks.  She has never experienced bleeding or cramping in between periods in the past.
Client reported large hard knot at site of injection, hot and red, and entire upper arm swelling for several days.  As arm swelling went down, a red itchy rash then was noted on entire upper arm started, and has lasted until a return visit 10-24-16.  Client was advised to use a topical cream for the intense itching sensation.
27SEP95 5AM inj site red, tennis ball size lump; used ice pack & APAP; 27SEP95 PM mom reports no change @ inj site, cont to be red, warm to touch, no significant temp; will cont & APAP 3OCT95-swelling from inj has completely resolved, pt OK
Patient developed a rash that progressed. Patient was seen by his doctor 1 day and 4 days post vaccination and it was determined that the reaction was significant enough that he should not receive a second dose of the vaccine.
ipsilateral supraclavicular lymphadenopathy after covid 19 vaccination; The pain and swelling was excruciating; The pain and swelling was excruciating; The vaccine was given to high in the deltoid; This is a spontaneous report received from a contactable reporter(s) (Other HCP). The reporter is the patient.  A 55 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), intramuscular, administered in deltoid right, administration date 25Jan2022 10:30 (Lot number: 33036BD) at the age of 55 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "Goji Berries allergy" (unspecified if ongoing); "High Cholesterol" (unspecified if ongoing); "Gerd" (unspecified if ongoing); "Migraines" (unspecified if ongoing). Concomitant medication(s) included: LIPITOR. Past drug history included: Flu vaccine, reaction(s): "Allergy". Vaccination history included: Bnt162b2 (Dose Number: 2, Batch/Lot No: FC3183, Location of injection: Arm Right, Route of Administration: Intramuscular), administration date: 31Aug2021, when the patient was 55 years old, for COVID-19 immunization; Bnt162b2 (Dose Number: 1, at 12:30 PM, Batch/Lot No: FA7485, Location of injection: Arm Right, Route of Administration: Intramuscular), administration date: 10Aug2021, when the patient was 55 years old, for COVID-19 immunization. The following information was reported: INCORRECT ROUTE OF PRODUCT ADMINISTRATION (non-serious) with onset 25Jan2022 10:30, outcome "not recovered", described as "The vaccine was given to high in the deltoid"; LYMPHADENOPATHY (non-serious) with onset 25Jan2022 20:00, outcome "not recovered", described as "ipsilateral supraclavicular lymphadenopathy after covid 19 vaccination"; SWELLING (non-serious), PAIN (non-serious) all with onset 25Jan2022 20:00, outcome "not recovered" and all described as "The pain and swelling was excruciating". The events "the vaccine was given to high in the deltoid", "ipsilateral supraclavicular lymphadenopathy after covid 19 vaccination", "the pain and swelling was excruciating" and "the pain and swelling was excruciating" were evaluated at the emergency room visit. Therapeutic measures were taken as a result of incorrect route of product administration, lymphadenopathy, swelling, pain.  Additional Information: As treatment patient received Toradolim and Muscle Relaxant. Covid was prior vaccination. Covid was not tested post vaccination.  No follow-up attempts are possible. No further information is expected.  Follow-up (07Feb2022): Follow-up attempts are completed. No further information is expected.
Pt had chest pressure and slight pain starting 10 minutes after the injection. Patient then had worsening chest pressure and pain, slight nausea, dizziness, palpitations, and left upper extremity paresthesia which lasted a few minutes. The symptoms resolved but hen recurred later when she was in the post-vaccine monitoring area. Pt also felt pre-syncopal and was then sent to the emergency department. Her symptoms resolved shortly thereafter but she had an additional episode while waiting in the ED. She reports she currently feels some chest pressure and LUE burning. No exacerbating or alleviating factors. Not associated with shortness of breath.
pt recv 2 doses of vax 15AUG96 & 18SEP96 & 23OCT96 pt exp lack serconversion;no further details were provided;
I had chronic cough and congestion. I took two at home test and they were negative. I went to the clinic and tested there and it came back positive. I called the doctor and I was prescribed Paxlovid for 5 days.
Severe left shoulder and chest pain. Diagnosed as acute brachioplexitis 2 hours after flu shot. required IV, Dicandin and hospitalization for four days to control the pain and to rule out MI. Complete recovery after oral steroids and physical therapy one month later.
Extreme dizziness patient unable to stand for last 36 hours with feeling like she is about to fall on her face. Also unable to seek medication attention, she is widowed, lives alone, no one to drive to seek medical attention which was recommended by poison control center on 9/29/2018.
Headache 2 days later for 3 days. Yesterday 8-19 at 4 pm had chills, fever, and aches
Bad headache, real tired, did not feel all that well sort of sick to my  stomach.  Also I could not sleep on my left side that evening. ( that was the side I got vaccine in)
80-year-old female receives her first dose of Pfizer at 5:30pm. After completing her 30 minute's in the observation area the paramedic approaches to ask her how she feels or if she has itching and she refers to feeling difficulty swallowing. Patient was taken to the observation area and incidents in a wheelchair to take vital signs which were: 130.80 mmHg, Sat.99% with clear lungs on auscultation,19 breaths, no upper airway edema and respiratory stridor. The case was consulted with Doctor at 6:17pm which indicated administering 4 mg of Dexamethasone IM in the buttock left upper outer. The patient was kept under observation and after 30 minutes she indicated that she was not felt the aforementioned symptoms. Before being discharged, her vitals were taken again which were: 130/80mmHg, 19 breaths with clear lungs on auscultation, no upper airway edema, 83 with a strong and regular pulse.
We dispensed 28 doses of expired Moderna covid-19 vaccine; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (We dispensed 28 doses of expired Moderna covid-19 vaccine) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012H21B) for COVID-19 vaccination.     No known allergies.     On 08-Apr-2022, the patient received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 08-Apr-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (We dispensed 28 doses of expired Moderna covid-19 vaccine). At the time of the report, EXPIRED PRODUCT ADMINISTERED (We dispensed 28 doses of expired Moderna covid-19 vaccine) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was provided. Patient had never been diagnosed/tested positive for Covid-19. Patient did not receive other vaccines within 1 month prior to Moderna COVID-19 vaccine. The patient did not report any adverse event after vaccine administered.  No temperature excursions were reported. No treatment medication was provided.
Dyspnea, chest pressure, fatigue.  Sought care at the hospital/ED -- found to have acute pulmonary emboli (by CT) with hypoxic respiratory failure.  Treated with hospitalization, Xarelto, nasal canula oxygen. She improved to be stable on room air with improvement of her symptoms and went home after 3 days.
Redness, pain, significant swelling at injection site on left arm. All adverse events got worse and patient was advised by nurse to visit ER. (Time of onset is approximated).
Approximately six hours after vaccines given, patient awoke from nap with decreased activity and episode of cyanosis.  No WOB, respiratory distress, activity, etc.  Full sepsis work up with treatment possible UTI (uncircumcised male).
+ Ag home test for covid on 24Jan positive; illness mild cough loss of smell and fatigue starting 1/23 and + Ag home test for Covid on 24Jan positive; This is a spontaneous report received from a non-contactable reporter(s) (Other HCP).  A 43 year-old male patient received bnt162b2 (BNT162B2), administration date 21Dec2021 (Lot number: FF2589) at the age of 43 years as dose 3 (booster), single, administration date 24Feb2021 (Lot number: EL3247) as dose 2, single and administration date 02Feb2021 (Lot number: EL3247) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: VACCINATION FAILURE (medically significant) with onset 24Jan2022, outcome "recovering", described as "+ Ag home test for covid on 24Jan positive"; COVID-19 (medically significant) with onset 23Jan2022, outcome "recovering", described as "illness mild cough loss of smell and fatigue starting 1/23 and + Ag home test for Covid on 24Jan positive". The patient underwent the following laboratory tests and procedures: sars-cov-2 test positive: (24Jan2022) positive. It was unknown if therapeutic measures were taken as a result of vaccination failure, covid-19.  Additional information: Unknown if other vaccine was taken in four weeks. Unknown if covid-19 prior vaccination.   No follow-up attempts are possible. No further information is expected.; Sender's Comments: The vaccine efficacy varies from one patient to another and can be affected by different factors; however, a contributory role of the suspect vaccine BNT162B2 to vaccination failure cannot be ruled out.
The next day I had full body aches, fatigue and exhaustion and low grade fever and no appetite. I developed a severe rash where I got the injection. The fever and body aches just lasted to Friday. Saturday, I still had the rash area on my arm and it got bigger.  Saturday   - Telehealth visit. Rash on arm took five days to go away. Told me to put a  hot compress on it if I wanted to but no other advice given. Pregnancy - February 12 - Preeclampsia was diagnosed. I was induced that day so baby was a week early -. February 20 had been estimated due date. This was my first pregnancy. I got COVID when I was pregnant in October. I was hospitalized with the heart rate issue that they thought occurred because of COVID November 16-19th. I have a healthy baby girl!
Delayed anaphylactic reaction with severe hives, difficulty breathing, fever, nausea, dizziness, neck pain and spasms, shakiness, weakness in both arms and blurred vision. Made 3 trips to ER for Epinephrine and several meds; eye drops; and physical therapy is still on-going.
Arm is red, swollen, extremely sore and somewhat itchy. I cannot raise arm above my head without pain. I have had PREVNAR 13 previously w/mild reaction, but PREVNAR 23 produced symptoms that are moderate to severe.
10 Patients administered vaccine past the beyond use date; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (10 Patients administered vaccine past the beyond use date) in a 75-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 939905) for COVID-19 vaccination.     No Medical History information was reported.   On 05-Nov-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (10 Patients administered vaccine past the beyond use date). On 05-Nov-2021, EXPIRED PRODUCT ADMINISTERED (10 Patients administered vaccine past the beyond use date) had resolved.      For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication information was provided. No treatment medication were provided.
Patient developed vesicular clusters with about 10 vesicles over about a 3 centimeter diameter on the inside of her right arch and then has a similar cluster up on the outside of her right thigh. No other rash is noted around her right leg. Has no apparent pain in her back or buttock.  This began on 12/5/08, just 14 days after receiving Zostravax.  Patient stated that this rash itches but no significant pain associated with it. Patient was started on Prednisone 20 mg. 2 tabs (40 mg.) x 4 days, then 1 tab for 4 days.  Valacyclovir 1 G tabs, 1 tab 3 times a day x 7 days.
Swollen, red, hot, broken blood vessels. Cellulitis is the final diagnosis.  Treatment is antibiotics for 10 days.
he missed his 2nd dose; This spontaneous case was reported by a nurse and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (he missed his 2nd dose) in a 63-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 042L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 01-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Mar-2021, the patient experienced PRODUCT DOSE OMISSION ISSUE (he missed his 2nd dose). At the time of the report, PRODUCT DOSE OMISSION ISSUE (he missed his 2nd dose) had resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   concomitant medications were reported included Psychiatric medications.  No treatment information was provided.  Patient was due for second dose of Moderna COVID-19 Vaccine on 01 Mar 2021.Patient has not received dose as facility is not allowing patient to have vaccine from primary care physician.
Pt has a 2cm X 1cm red, raised, itching wheal on upper, posterior aspect of right upper arm. It was 1st noticed by the pt on 10/19/01. On 10/23/01, it was measured by clinic nurse and it was 2cm X 1 1/2cm. It was treated with topical application of hydrocortisone cream. On 10/15/01, PPD was placed on left forearm. PPD-OMM on 10/18/01. Temperature was 100.5F-101F on 10/19/01 until 10/21/01.
SPINAL CORD RUPTURED; PARALYZED; TRANSVERSE MYELITIS; DEMYELINATION OF THE SPINAL CORD; This spontaneous report received from a consumer via social media via a company representative concerned a male of unspecified age, race and ethnic origin. The patient's height and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin and batch number were not reported, expiry: unknown) dose and start therapy date were not reported, 1 total administered for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported. On an unspecified date, the patient experienced spinal cord ruptured, paralyzed, transverse myelitis, and demyelination of the spinal cord, and was hospitalized (date unspecified). It was reporter that "one of the guys who spoke out, had a really severe reaction to the Johnson and Johnson vaccine and it caused transverse myelitis, which was basically the demyelination of the spinal cord, and so what happened to him was his spinal cord ruptured and now he was paralyzed and he spent 30 days in the hospital and the first 30 days in the hospital cost him 1.2 million dollars." The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from paralyzed, and the outcome of transverse myelitis, spinal cord ruptured and demyelination of the spinal cord was not reported. This report was serious (Hospitalization Caused / Prolonged). This case, from the same reporter is linked to 20220112025.; Sender's Comments: V0: This spontaneous report received from a consumer via social media via a company representative concerned a man of unspecified age, race and ethnic origin who experienced transverse myelitis and demyelination on an unspecified day after vaccination. The patient's medical history, concomitant medications, treatment, lab work and diagnostics were not reported. On an unspecified date, the patient experienced spinal cord rupture, paralysis, transverse myelitis, demyelination of the spinal cord, and spent 30 days in the hospital. However, the patient had not recovered from paralysis and the outcome of transverse myelitis, spinal cord rupture and demyelination of the spinal cord was not reported. Information regarding other potential etiologies was insufficient, and the occurrence of such events could represent background incidence in the general population. Considering the temporal relationship, the event is assessed to have an indeterminate relationship with vaccination.
This spontaneous report as received from a registered nurse refers to an unknown number of patients of unknown age and gender. The patient's pertinent medical history or concurrent conditions were not provided. On an unknown dates, the patients were vaccinated with improperly stored doses of MMR II, (Lot # reported as L015281 and expiry date on 30-APR-2017) (dose and route of administration were not provided). No adverse events were reported. This is one of several reports received from the same source. Additional information has been requested.
Received Tdap and MVO in LD on 03-03-2015. Client c/o headaches and LD swollen, red, and warm to touch. Client was seen at HD at 2:30 pm 3-5-15.
arm froze up; broke out in a rash; ran fever; lost the skin on my hands; sick for the next 10 months; This case was reported by a consumer via interactive digital media and described the occurrence of mobility decreased in a adult patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   In November 2020, the patient received the 1st dose of Shingles vaccine. On an unknown date, less than 9 months after receiving Shingles vaccine, the patient experienced mobility decreased, rash, fever, skin loss and sickness. On an unknown date, the outcome of the mobility decreased, rash, fever, skin loss and sickness were unknown.   It was unknown if the reporter considered the mobility decreased, rash, fever, skin loss and sickness to be related to Shingles vaccine.  Additional details were reported as follows: The age at vaccination was not reported. The age group was not reported but it was captured as adult as per vaccine indication. The patient's arm froze up, he or she broke out in a rash, ran fever, lost the skin on hands and sick for the next 10 months.  The patient was not getting second dose. The patient wanted to but was not able to post a pic.
Facial redness/ Flushing per patient - Tachycardia and Increased Blood Pressure (secondary possibly to stress/nervousness)
Fever, malaise, chills, body aches, nausea and fatigue for about 17 hours
Expired product administered; No adverse effect; This spontaneous report was received from a nurse prescriber and refers to a patient of unknown age and gender. The patient's relevant medical history, concomitant medications and concurrent conditions were unknown.  On 13-MAY-2019, the patient was vaccinated with an expired dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live(M-M-R II) lot # N014483 and expiration date 20-MAY-2019, for prophylaxis (dose, strength,and route of administration were unknown).         No adverse effects were reported.
Below the site of injection was hot; Below the site of injection was puffy; Belowthe site of injection was red; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE WARMTH (Below the site of injection was hot), VACCINATION SITE SWELLING (Below the site of injection was puffy) and VACCINATION SITE ERYTHEMA (Belowthe site of injection was red) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 23-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Feb-2021, the patient experienced VACCINATION SITE WARMTH (Below the site of injection was hot), VACCINATION SITE SWELLING (Below the site of injection was puffy) and VACCINATION SITE ERYTHEMA (Belowthe site of injection was red). At the time of the report, VACCINATION SITE WARMTH (Below the site of injection was hot), VACCINATION SITE SWELLING (Below the site of injection was puffy) and VACCINATION SITE ERYTHEMA (Belowthe site of injection was red) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.  Treatment details was not provided.
Rash (leaky capillaries) on leg that had appeared March 2020 post illness  flared up again after it had started to subside. Later leading to splotches on distill lower leg along saphenous vein. Splotches resembled thombopenia purpua but to a lesser extent. The splotches then became dry scales of dead skin if pealed or scratched would open a vein underneath. Also flare ups of itchy rash with hives ,when touching skin, randomly occurring then fading away.